TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients
| TCONDelisted Stock | USD 1.60 0.55 52.38% |
About 55% of TRACON Pharmaceuticals' investors are presently thinking to get in. The analysis of overall sentiment of trading TRACON Pharmaceuticals stock suggests that some investors are interested at this time. TRACON Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in TRACON Pharmaceuticals. Many technical investors use TRACON Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
TRACON |
Publication Highlights Activity of the Combination of TRC102 and Temodar in Patients who Progressed Following Initial Treatment with Surgical Resection, Temodar and External Beam Radiotherapy Consistent with the TRC102 Mechanism of Action, Extended Survival was Demonstrated in Patients with Activation of DNA Damage Response Pathways Prior to TRC102 Treatment SAN DIEGO, June 11, 2024 -- TRACON Pharmaceuticals , a clinical stage biopharmaceutical compa
Read at finance.yahoo.com
 |
TRACON Pharmaceuticals Fundamental Analysis
We analyze TRACON Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of TRACON Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of TRACON Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Asset
Total Asset Comparative Analysis
TRACON Pharmaceuticals is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
TRACON Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with TRACON Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of TRACON Pharmaceuticals could also be used in its relative valuation, which is a method of valuing TRACON Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
TRACON Pharmaceuticals Related Equities
| ANTX | AN2 Therapeutics | 21.90 | ||||
| MNPR | Monopar Therapeutics | 8.84 | ||||
| VINC | Vincerx Pharma | 7.69 | ||||
| CADL | Candel Therapeutics | 7.14 | ||||
| IKT | Inhibikase Therapeutics | 6.96 | ||||
| CYCN | Cyclerion Therapeutics | 1.85 | ||||
| PMVP | Pmv Pharmaceuticals | 1.25 | ||||
| ADXN | Addex Therapeutics | 1.04 | ||||
| RZLT | Rezolute | 1.00 | ||||
| ACHL | Achilles Therapeutics | 0.93 | ||||
| ACXP | Acurx Pharmaceuticals | 0.88 | ||||
| XOMA | XOMA Corp | 0.84 | ||||
| ANEB | Anebulo Pharmaceuticals | 0.70 | ||||
| TPST | Tempest Therapeutics | 1.04 | ||||
| KRON | Kronos Bio | 1.04 | ||||
| ENTX | Entera Bio | 3.53 | ||||
| LRMR | Larimar Therapeutics | 4.67 |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Other Consideration for investing in TRACON Stock
If you are still planning to invest in TRACON Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the TRACON Pharmaceuticals' history and understand the potential risks before investing.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |